Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 30Tumor-Agnostic 2NET 1Endocrine 1

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × folfirinox × NET × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡